7,884 Shares in Eli Lilly and Company $LLY Purchased by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. bought a new position in Eli Lilly and Company (NYSE:LLY) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 7,884 shares of the company’s stock, valued at approximately $7,254,000.

Other institutional investors have also recently made changes to their positions in the company. Maryland Capital Advisors Inc. purchased a new stake in Eli Lilly and Company in the fourth quarter worth approximately $25,000. Osbon Capital Management LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth $30,000. Maseco LLP grew its holdings in shares of Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after acquiring an additional 28 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Cantor Fitzgerald raised their target price on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a report on Friday, May 22nd. Guggenheim lifted their price target on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Finally, Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Two analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,283.64.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor interest remains strong in Eli Lilly thanks to its leadership in the fast-growing weight-loss and GLP-1 drug market, which continues to support long-term growth expectations.
• Positive Sentiment: Articles highlighting a possible stock split suggest shares trading above $1,000 could make LLY more accessible to retail investors and keep demand elevated.
• Positive Sentiment: Erste Group Bank issued an optimistic earnings estimate for LLY, reinforcing confidence in the company’s strong profit outlook.
• Neutral Sentiment: Coverage describing Eli Lilly as a trending stock shows the name remains heavily watched, which can amplify moves but does not by itself change fundamentals.
• Neutral Sentiment: Several valuation-focused articles argue the stock looks expensive or fully valued after its massive multi-year rally, suggesting expectations are already high.
• Neutral Sentiment: News about Eli Lilly’s $3.8 billion psychedelic-medicine deal and commentary around the ATAI buyout are more about strategic expansion than immediate revenue impact.
• Negative Sentiment: Recent commentary that LLY may be fully valued, stretched, or expensive has likely added to profit-taking pressure after the stock’s strong advance.
• Negative Sentiment: One market recap noted Eli Lilly fell more than the broader market in the latest session, reflecting a weaker short-term trading tone.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,146.90 on Tuesday. The stock’s 50 day simple moving average is $1,122.49 and its two-hundred day simple moving average is $1,036.98. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a market cap of $1.08 trillion, a price-to-earnings ratio of 40.74, a PEG ratio of 1.48 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the business earned $3.34 earnings per share. Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 34.55 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.